narsoplimab · Yartemlea

Monoclonal antibody

Also known as OMS721

Approvedregulatory verdict

Evidence outlook

Approved: Thrombotic Microangiopathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT03608033 · Omeros Corporation
2018-04-05 – 2024-01-12 · IgA Nephropathy
What this study did
Phase 2 (4)
Other / comorbidity
NCT04488081 · QuantumLeap Healthcare Collaborative
2020-07-31 – 2030-07-31 · COVID-19
What this study did
NCT05855083 · Omeros Corporation
2023-05-01 – 2025-12 · Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
What this study did
NCT02682407 · Omeros Corporation
2016-03-10 – 2020-08-25 · IgAN, LN, MN, C3G
What this study did

Competitive landscape

This drug's own stage for Thrombotic Microangiopathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Narsoplimab (Yartemlea): this drugApprovedMonoclonal antibodyMASP-2not yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Yartemlea (narsoplimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
Phase 2COVID-19Active not recruiting
Est. primary completion 2028-07-31 · NCT04488081 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 October 2026Advisory committeeEMA confirms its recommendation to refuse marketing authorisation for Yartemlea (narsoplimab) after re-examination (CHMP negative opinion of 25 June 2026)
EU, EMA · European Medicines Agency · Source ↗